Juan Jose Badimon

Summary

Affiliation: Mount Sinai School of Medicine
Country: USA

Publications

  1. pmc Differences in thrombus structure and kinetics in patients with type 2 diabetes mellitus after non ST elevation acute coronary syndrome
    Girish N Viswanathan
    Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK Electronic address
    Thromb Res 133:880-5. 2014
  2. ncbi request reprint [Importance of HDL cholesterol in atherothrombosis: how did we get here? Where are we going?]
    Juan Jose Badimon
    Unidad de Investigación de Aterotrombosis, Instituto Cardiovascular, Mount Sinai School of Medicine, Nueva York, NY 10029, Estados Unidos
    Rev Esp Cardiol 63:20-35. 2010
  3. doi request reprint Genesis and dynamics of atherosclerotic lesions: implications for early detection
    Juan Jose Badimon
    Atherothrombosis Research Unit, Cardiovascular Institute, The Mount Sinai School of Medicine, New York, NY 10029, USA
    Cerebrovasc Dis 27:38-47. 2009
  4. ncbi request reprint Atherothrombosis: the role of tissue factor
    Juan F Viles-Gonzalez
    Cardiovascular Biology Research Laboratory, Zena and Michael A Wiener Cardiovascular Institute, Mount Sinai School of Medicine, One Gustave L Levy Place, P O Box 1030, New York, NY 10029, USA
    Int J Biochem Cell Biol 36:25-30. 2004
  5. ncbi request reprint Increasing high-density lipoprotein as a therapeutic target in atherothrombotic disease
    Juan Jose Badimon
    Atherothrombosis Research Unit, Cardiovascular Institute, Mount Sinai Hospital, New York, NY 10029, USA
    Rev Esp Cardiol 63:323-33. 2010
  6. ncbi request reprint The vulnerable plaque and acute coronary syndromes
    Roberto Corti
    Cardiovascular Biology Research Laboratory, Mount Sinai School of Medicine, New York, New York, USA
    Am J Med 113:668-80. 2002
  7. ncbi request reprint Biologic aspects of vulnerable plaque
    Roberto Corti
    Cardiovascular Biology Research Laboratory and the Zena and Michael A Wiener Cardiovascular Institute, Mount Sinai School of Medicine, New York, NY 10029, USA
    Curr Opin Cardiol 17:616-25. 2002
  8. ncbi request reprint Pathogenetic concepts of acute coronary syndromes
    Roberto Corti
    Zena and Michael A Wiener Cardiovascular Institute, The Mount Sinai School of Medicine, New York, New York 10029, USA
    J Am Coll Cardiol 41:7S-14S. 2003
  9. ncbi request reprint Role of risk factors in the modulation of tissue factor activity and blood thrombogenicity
    Antonia Sambola
    Cardiovascular Biology Research Laboratory, Mount Sinai School of Medicine, New York, NY 10029, USA
    Circulation 107:973-7. 2003
  10. ncbi request reprint Evolving concepts in the triad of atherosclerosis, inflammation and thrombosis
    Roberto Corti
    Zena and Michael A Wiener Cardiovascular Institute, The Mount Sinai School of Medicine, New York, NY 10029, USA
    J Thromb Thrombolysis 17:35-44. 2004

Research Grants

Detail Information

Publications22

  1. pmc Differences in thrombus structure and kinetics in patients with type 2 diabetes mellitus after non ST elevation acute coronary syndrome
    Girish N Viswanathan
    Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK Electronic address
    Thromb Res 133:880-5. 2014
    ..Despite optimal secondary prevention therapy following non-ST elevation acute coronary syndrome (NSTE-ACS), recurrent thrombotic events are more frequent in patients with type 2 diabetes mellitus (T2DM)...
  2. ncbi request reprint [Importance of HDL cholesterol in atherothrombosis: how did we get here? Where are we going?]
    Juan Jose Badimon
    Unidad de Investigación de Aterotrombosis, Instituto Cardiovascular, Mount Sinai School of Medicine, Nueva York, NY 10029, Estados Unidos
    Rev Esp Cardiol 63:20-35. 2010
    ....
  3. doi request reprint Genesis and dynamics of atherosclerotic lesions: implications for early detection
    Juan Jose Badimon
    Atherothrombosis Research Unit, Cardiovascular Institute, The Mount Sinai School of Medicine, New York, NY 10029, USA
    Cerebrovasc Dis 27:38-47. 2009
    ....
  4. ncbi request reprint Atherothrombosis: the role of tissue factor
    Juan F Viles-Gonzalez
    Cardiovascular Biology Research Laboratory, Zena and Michael A Wiener Cardiovascular Institute, Mount Sinai School of Medicine, One Gustave L Levy Place, P O Box 1030, New York, NY 10029, USA
    Int J Biochem Cell Biol 36:25-30. 2004
    ..Ongoing clinical and preclinical studies are evaluating the therapeutic possibilities of specific inhibition of the tissue factor pathway. Here, we will review the role of tissue factor in atherothrombosis...
  5. ncbi request reprint Increasing high-density lipoprotein as a therapeutic target in atherothrombotic disease
    Juan Jose Badimon
    Atherothrombosis Research Unit, Cardiovascular Institute, Mount Sinai Hospital, New York, NY 10029, USA
    Rev Esp Cardiol 63:323-33. 2010
    ..Nevertheless, despite statin treatment, a large percentage of patients continues to experience cardiovascular events. Therapies aimed at increasing HDL have been investigated for several decades, with promising..
  6. ncbi request reprint The vulnerable plaque and acute coronary syndromes
    Roberto Corti
    Cardiovascular Biology Research Laboratory, Mount Sinai School of Medicine, New York, New York, USA
    Am J Med 113:668-80. 2002
    ..These regimens focus on inhibiting thrombin, preventing thrombi generation, blocking the initiation of coagulation, inhibiting platelet activation, and increasing fibrinolysis...
  7. ncbi request reprint Biologic aspects of vulnerable plaque
    Roberto Corti
    Cardiovascular Biology Research Laboratory and the Zena and Michael A Wiener Cardiovascular Institute, Mount Sinai School of Medicine, New York, NY 10029, USA
    Curr Opin Cardiol 17:616-25. 2002
    ....
  8. ncbi request reprint Pathogenetic concepts of acute coronary syndromes
    Roberto Corti
    Zena and Michael A Wiener Cardiovascular Institute, The Mount Sinai School of Medicine, New York, New York 10029, USA
    J Am Coll Cardiol 41:7S-14S. 2003
    ..As a consequence of the central role of endothelial cells in hemostatic control, a dysfunctional endothelium will generate a pro-thrombotic environment favoring development of atherosclerotic lesions and thrombotic complications...
  9. ncbi request reprint Role of risk factors in the modulation of tissue factor activity and blood thrombogenicity
    Antonia Sambola
    Cardiovascular Biology Research Laboratory, Mount Sinai School of Medicine, New York, NY 10029, USA
    Circulation 107:973-7. 2003
    ..We have extended our study to smokers and hyperlipidemic subjects...
  10. ncbi request reprint Evolving concepts in the triad of atherosclerosis, inflammation and thrombosis
    Roberto Corti
    Zena and Michael A Wiener Cardiovascular Institute, The Mount Sinai School of Medicine, New York, NY 10029, USA
    J Thromb Thrombolysis 17:35-44. 2004
    ..Inflammation, thrombosis and atherosclerosis are interdependent and define a triad within the complex pathogenic process of atherothrombosis...
  11. ncbi request reprint Statins and plaque stability
    Mardi Gomberg-Maitland
    Mount Sinai Medical Center, Department of Cardiology, New York, NY 10129, USA
    J Cardiovasc Risk 10:161-7. 2003
    ..This review will discuss the pharmacology, clinical trials, and mechanisms, besides lipid lowering, of statin therapy...
  12. doi request reprint Pathophysiological role of blood-borne tissue factor: should the old paradigm be revisited?
    Giovanni Cimmino
    Atherothrombosis Research Unit, Mount Sinai Hospital, New York, NY, USA
    Intern Emerg Med 6:29-34. 2011
    ..g., blood-borne tissue factor, may represent a useful tool to identify patients with a high-risk profile of developing major cardiovascular events...
  13. doi request reprint Coronary artery disease in aging women: a menopause of endothelial progenitor cells?
    Randolph Hutter
    Mount Sinai School of Medicine, New York, NY 10029 6574, USA
    Med Clin North Am 96:93-102. 2012
    ....
  14. ncbi request reprint The Mikamo Lecture 2002. Therapeutic targets for the treatment of atherothrombosis in the new millennium--clinical frontiers in atherosclerosis research
    Valentin Fuster
    The Zena and Michael Wiener Cardiovascular Institute, Mount Sinai School of Medicine, New York, NY 10029, USA
    Circ J 66:783-90. 2002
  15. doi request reprint Pathophysiology of acute coronary syndrome
    Carlos G Santos-Gallego
    Atherothrombosis Research Unit, The Zena and Michael A Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, One Gustave Levy Place, Box 1030, New York, NY, 10029, USA
    Curr Atheroscler Rep 16:401. 2014
    ..In the hope of improving our understanding of ACS, all these recently discovered concepts are reviewed in this article. ..
  16. doi request reprint Increasing high-density lipoprotein as a therapeutic target in atherothrombotic disease
    Juan Jose Badimon
    Atherothrombosis Research Unit, Cardiovascular Institute, Mount Sinai Hospital, New York, USA
    Rev Esp Cardiol (Engl Ed) 63:323-33. 2010
    ..This review describes the biological rationale underlying the use of treatments that increase HDL and discusses the potential benefits of such treatment. ..
  17. ncbi request reprint Thrombi of different pathologies: implications for diagnosis and treatment
    Carlos G Santos-Gallego
    Atherothrombosis Research Unit, The Zena and Michael A Wiener Cardiovascular Institute, 1 Gustave Levy Place, Box 1030, Mount Sinai School of Medicine, New York, NY, 10029, USA
    Curr Treat Options Cardiovasc Med 12:274-91. 2010
    ..Currently, carotid endarterectomy surgery is superior to carotid angioplasty and stenting...
  18. doi request reprint Experimental models for the investigation of high-density lipoprotein-mediated cholesterol efflux
    Carlos G Santos-Gallego
    Atherothrombosis Research Unit, The Zena and Michael A Wiener Cardiovascular Institute, Mount Sinai School of Medicine, One Gustave Levy Place, Box 1030, New York, NY 10029, USA
    Curr Atheroscler Rep 13:266-76. 2011
    ..Measuring the in vivo function of HDL could be of significant importance for both the clinical evaluation of an individual patient and to evaluate the effectiveness of different RCT-enhancing therapeutic approaches...
  19. ncbi request reprint Antithrombotic effects of DX-9065a, a direct factor Xa inhibitor: a comparative study in humans versus low molecular weight heparin
    Daichi Shimbo
    Cardiovascular Biology Research Laboratory, Mount Sinai School of Medicine, New York, NY 10029, USA
    Thromb Haemost 88:733-8. 2002
    ..Several inhibitors of TF, coagulation factors VIIa and Xa are under investigation as novel antithrombotic approaches. We compared the antithrombotic effects of DX-9065a, a new FXa inhibitor, vs. enoxaparin...
  20. ncbi request reprint Clinical implications of clopidogrel resistance
    Antonio de Miguel
    Atherothrombosis Research Unit, The Zena and Michael A Wiener Cardiovascular Institute, Mount Sinai School of Medicine, New York, NY 10029, USA
    Thromb Haemost 100:196-203. 2008
    ....
  21. ncbi request reprint From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I
    Morteza Naghavi
    The Center for Vulnerable Plaque Research, University of Texas Houston, The Texas Heart Institute, and President Bush Center for Cardiovascular Health, Memorial Hermann Hospital, Houston, USA
    Circulation 108:1664-72. 2003
    ..We encourage healthcare policy makers to promote translational research for screening and treatment of vulnerable patients...
  22. ncbi request reprint Can we image the "active" thrombus?
    Juan Jose Badimon
    Arterioscler Thromb Vasc Biol 22:1753-4. 2002

Research Grants1

  1. Translational Studies of Depression, Platelets, & CAD
    Juan Badimon; Fiscal Year: 2006
    ..abstract_text> ..